CMG Pharmaceutical Co., Ltd. (KOSDAQ:058820)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,767.00
+51.00 (2.97%)
Mar 20, 2026, 3:30 PM KST
Market Cap261.24B -3.5%
Revenue (ttm)100.41B +6.4%
Net Income-9.59B
EPS-80.33
Shares Out147.84M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,608,523
Average Volume1,131,399
Open1,719.00
Previous Close1,716.00
Day's Range1,719.00 - 1,799.00
52-Week Range1,670.00 - 3,345.00
Beta0.62
RSI43.88
Earnings DateMar 27, 2026

About CMG Pharmaceutical

CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic collaboration agreement with Handok Inc. for cancer treatment. The company was formerly known as Skynewpharm Co Ltd and changed its name to CMG Pharmaceutic... [Read more]

Sector Healthcare
Founded 2001
Employees 223
Stock Exchange KOSDAQ
Ticker Symbol 058820
Full Company Profile

Financial Performance

In 2024, CMG Pharmaceutical's revenue was 99.10 billion, an increase of 5.53% compared to the previous year's 93.91 billion. Earnings were 2.69 billion, a decrease of -58.26%.

Financial Statements